DỮ LIỆU BÁO CÁO THƯỜNG NIÊN
CÁC CÔNG TY NIÊM YẾT NƯỚC NGOÀI

Báo cáo thường niên năm 2019 của AEterna Zentaris Inc.

Aeterna Zentaris Inc. is a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests. The Company’s lead product, Macrilen™ (macimorelin), is the first and only U.S. FDA and European Commission approved oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). Macrilen™ is currently marketed in the United States through a license agreement with Novo Nordisk and Aeterna Zentaris receives double-digit royalties on sales. Aeterna Zentaris owns all rights to macimorelin outside of the U.S. and Canada.

TÊN CÔNG TY / COMPANY
AEterna Zentaris Inc.

SÀN CHỨNG KHOÁN / STOCK EXCHANGE
TSX (Canada)

MÃ CHỨNG KHOÁN / TICKER
AEZS

KỲ BÁO CÁO
2019

NGÀNH / INDUSTRY
Biotechnology

LĨNH VỰC / SECTOR
Healthcare